Retour aux projets

12985.1;6 PFLS-LS

Design, optimization and validation of compounds against cancer-Initiating cells.

Résumé

Design, optimization and validation of compounds against cancer-Initiating cells.

Textes supplémentaires

Abstract

This CTI project aims at identifying a preclinical candidate and generate a selection of back-up compounds to treat brain cancer, in order to accelerate and improve the development programs of Stemergie Biotechnology SA. The combination of the unique technology expertise of Stemergie in cancer-initiating cells with the medicinal chemistry technologies and know-how of the Carreira Group at the ETH Zurich shall enable the development of novel drug candidates to treat brain cancer patients.

Participants

Erick M. Carreira

Kontaktperson

carreira@org.chem.ethz.ch

ETHZ D-CHAB Erick M. Carreira Wolfgang-Paulistr. 10 8093 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2011-11-14
Date de fin
2014-05-01
Coûts totaux approuvés
CHF 614000.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Nicht aufteilbare / nicht zuteilbare Forschung

Disciplines de recherche

  • T490 Biotechnology 100.0%